415 related articles for article (PubMed ID: 35257971)
1. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.
Torres-Castillo LC; Fandiño C; Ramos MP; Ramos-Castaneda JA; Rioseco ML; Juliet C
J Glob Antimicrob Resist; 2023 Dec; 35():143-148. PubMed ID: 37714380
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
Braz J Infect Dis; 2022; 26(3):102369. PubMed ID: 35618040
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019-2021.
Lemos-Luengas EV; Rentería-Valoyes S; Muñoz DMA; Gonzalez CKG; Guerrón-Gómez G; Ramos-Castaneda JA
Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116235. PubMed ID: 38458096
[TBL] [Abstract][Full Text] [Related]
5. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S; Wang H; Feng S
Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
[TBL] [Abstract][Full Text] [Related]
6.
Stone G; Wise M; Utt E
Microbiol Spectr; 2024 Mar; 12(3):e0147323. PubMed ID: 38329363
[TBL] [Abstract][Full Text] [Related]
7. Implementation of Chromatic Super CAZ/AVI
Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
[TBL] [Abstract][Full Text] [Related]
8. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
Lin LY; Debabov D; Chang W; Stone G; Riccobene T
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
[No Abstract] [Full Text] [Related]
10. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF
Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471
[TBL] [Abstract][Full Text] [Related]
11.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.
Zhen S; Lin Q; Chen Z; Shen Y; Chen X; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Jiang E; Han M; Wang J; Feng S
J Infect Chemother; 2024 Jul; 30(7):608-615. PubMed ID: 38215820
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators Against Fluoroquinolone-Resistant
Kiratisin P; Arhin FF; Stone G; Utt E
Microb Drug Resist; 2022 Nov; 28(11):1019-1027. PubMed ID: 36251881
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ko WC; Stone GG
Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019.
Tuan Soh TS; Salvinder S; Chen VSY
Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624
[TBL] [Abstract][Full Text] [Related]
16. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021.
Wise MG; Karlowsky JA; Hackel MA; Harti MA; Ntshole BME; Njagua EN; Oladele R; Samuel C; Khan S; Wadula J; Lowman W; Lembede BW; Sahm DF
J Glob Antimicrob Resist; 2023 Dec; 35():93-100. PubMed ID: 37709139
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
19. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
Rossolini GM; Stone GG
Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
